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ABSTRACT
Biochemical research and clinical studies have revolutionized the field of medicine in
both diagnosis and therapy. Researchers in the field of biochemistry and biotechnology are using
nanomaterials in different applications to develop devices and materials that offer benefits to
both patients and the health care industry. These include biochemical sensors, enzyme
encapsulation, biomarkers, and drug delivery improvements for the treatment of cancer. This
dissertation focuses on investigating two biochemical aspects using nanomaterials; namely
therapy and clinical diagnosis.
For therapy purposes, Silica nanoparticles were used as drug delivery system to develop a
new photodynamic cancer therapy agent photo-acid generator (PAG) that selectively induces
necrotic cell death of cancer cells. The developed PAG is oxygen-independent and - when
excited at specific wavelengths - drops the pH within the lysosome of cancer cells to produce
apoptosis/necrosis. It was specifically designed for in vivo applications and conjugated with
synthesized, highly monodispersed silica nanoparticles (Si NPs) functionalized with amine
groups via amid links (SiN-NH-PAG). Additional Features include high photo-acid quantum
yield, high one-photon (1PA) and two-photon absorption (2PA) with low fluorescence quantum
yield. In vivo, confocal microscope studies with HCT-116 (Human colorectal carcinoma) cancer
cells showed that photodynamic processes in the presence of PAG were completed under onephoton absorption (1PA) conditions. In these experiments, cells were imaged at 1 min intervals
for a total of 4 hours with the aid of Differential Interference Contrast (DIC). Among the
photodynamic therapy agents tested via cytotoxicity experiments with the MTS assay, (SiN-NHPAG) showed the best efficiency to induce cell death. The increased effectiveness of the new
agent is probably due to the large number of PAG groups present on the surface of Si NPs.
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Lysosome colocalization indicates that PAGs are mainly built in lysosomes. The increase of
acidic content inside the lysosome was demonstrated with the aid of the LysoSensor Green
probe. The drop in the intralysosomal pH was approximately 0.3 units. This is a desirable
outcome as most cells underwent necrosis at pH ≤ 4.4. For clinical diagnosis purposes, a
biochemical sensor was developed for the analysis of phosphate ions in urine samples. Abnormal
levels of inorganic phosphate in human urine samples are related to the development of certain
types of cancers affecting several organs of the human body, including breast, pancreas, lung and
thyroid. The new biochemical sensor is based on the fluorescence energy transfer between a
lanthanide luminescent probe [Tb-EDTA]-1 and gold nanoparticles (Au NPs) capped with a
Cetyltrimethylammonium bromide (CTAB) micelle. With this approach, it was possible to
selectively determine inorganic phosphate (Pi) in urine samples at the micro-molar concentration
level. Urine samples collected from healthy, non-smoking individuals showed no interference
from concomitants usually found in human urine samples. The simplicity of analysis provides an
approach well-suited for “real-time” monitoring of phosphate ions. Analysis time is made
possible within approximately 10 min per sample.
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CHAPTER 1. BACKGROUND
1.1

Cancer Diseases and Conventional Treatment Methods

Cancer is a group of diseases pertaining to abnormal cell growth with the possibility of
spreading to other parts of the body.1 Symptoms and signs associated with this disease are
abnormal bleeding, a prolonged cough, unusual weight loss, and a change in bowel movements. 2
This disease is responsible for 7.6 million deaths (around 13% of all deaths) worldwide in 2008. 3
The conventional methods for cancer treatment are chemotherapy, surgery, and radiotherapy.
However, chemotherapy treatment linked to a lot of problems and side effects. High
reappearance rate is associated with tumors surgical resection, while radiation is limited based on
cumulative radiation dose. Treatment with photodynamic therapy (PDT) is an alternative method
for tumor-ablative and function-sparing oncologic intervention.

1.2

Photodynamic Therapy

Photodynamic therapy (PDT) treatment started in early 1900s and its first demonstration
in 1975 by Dougherty et al4 this method undergo wide investigations and has been developed as
a disease site specific treatment modal. The basic mechanism for PDT involves the
administration of a tumor-localizing photosensitizer (PS) followed by illumination of a tumor
with light at a specific wavelength to excited the PS (Figure 1-1). The activated PS transfers its
energy to the oxygen generating cytotoxic reactive oxygen species (ROS) such as singlet oxygen
(1O2) that attach to cellular macromolecules leading to death of the tumor cell. Figure 1-2
represents stages of PDT: Stage I, injection of PS in the body; Stage II, chemicals concentrated

1

in the tumor site; Stage III, activated the PS using a light, and stage IIII, tumor selectively
destroyed. Unlike chemotherapy PDT employs three components (photosensitizer, oxygen, and
light), none of which have any toxic or damage effects on the neighboring normal tissues.
In the tissue, oxygen exists in the ground state as a triplet (nonreactive species).
However, when light is absorbed by the photosensitizer at a certain wavelength, PS will be
promoted to an excited state and transfer to a triplet state by intersystem crossing followed by
energy transfer from the PS to oxygen and excited it into a reactive singlet state.

Tissue
Oxygen
PS (excited state)

Free radicals,
singlet oxygen

light
PS
ground
state

Cellular toxicity

Figure 1-1. Schematic illustration of a typical photodynamic reaction based on photosensitizer
(PS).
Currently, many photosensitizer compounds such as porphyrin, texaphyrin, and chlorin
have been used clinically to treat different kinds of cancer such as skin cancer,

6,7

5

bladder

cancer,8 lung cancer,9 rectum and anus tumors.10 Promising results were also shown in the
treatment of brain tumors.11

2

Application-Local
Activation
Accumulation
or systemic

Apoptosis

Figure 1-2. Photodynamic therapy principle stages. Photosensitizer (in syringe or tube) is
injected locally or systemically (Stage I), accumulates in tumors (Stage II) and is then activated
by external illumination (Stage III), and cell damage and death (Stage IIII).

3

1.3

Drug delivery and Nanoparticles

Most of the drugs are hydrophobic therefore undergo a lot of problems of delivery in
blood circulation. As a result the efficacy of the therapeutic drug reduced. Many researches have
been done to deliver the hydrophobic drugs more efficiently using different methods like
encapsulating or conjugating them with nanoparticles. Figure 1-3

shows examples of

nanoparticles which are used to encapsulate drugs or conjugated drug molecules (12). Conjugation
or encapsulation of therapeutic drugs in nanoparticles has many advantages in comparison with
drug alone. For example, Doxorubicin encapsulated in polyethylene glycol coated Liposomes
(Doxil nanoparticles) have improved accumulation of doxorubicin and increased circulation time
compared to free doxorubicin.(13)
A.

B.

Amphiphilic copolymer

Polymer with pendant drugs

C. Lipids

Figure 1-3. A. polymeric micelles encapsulating therapeutic agents B. polymers conjugated with
therapeutic agents C. liposomes encapsulating therapeutic agents to enhance the
pharmacokinetics and pharmacodynamics by active intracellular delivery. (12)
4

Quantum dots CdSe-ZnS, encapsulated in ABC triblock copolymer conjugated with
tumor-targeting ligand and Poly ethylene glycol (PEG) were also used for drug delivery.(14) This
probe was coated with PEG to enhance the circulation in the blood while the ABC triblock were
used to protect the optical properties of Qdots in a broad variety of pH. The passive delivery for
prostate cancer was achieved by improved the circulation of the probe due to PEG while the
active delivery was achived by connecting the probe with prostate-specific membrane antigen
(PSMA) monoclonal antibody. Figures 1-4, 1-5 show the development of the probe and the
uptake of the probe in human prostate cancer cells that expressed and cells which do not express
s PSMA. Another examples of using nanoparticles for cancer therapeutics is reported.(15) They
used superpapamagnetic nanocrystals for MR imaging which encapsulated in silica nanoparticles
and the anticancer drug was stored inside. Silica nanoparticles were coated with phosphonate to
enhance the hydrophilicity and attached with folic acid to target the cancer cells. Figure 1-6
shows the increasing in the uptake of nanoparticles conjugated with folic acid in PANC-1, which
overexpresses folate receptors while HFF cells do not overexpress folate receptors.

5

Figure 1-4. Qdots probe development and depiction of passive and active tumor targeting. (14)
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QD-PSMA
C4-2 cells

QD-PEG
C4-2 cells

QD-PSMA
PC-3 cells

Figure 1-5. Qdot probe uptake in PSMA positive cells (C4-2) amd PSMA negative cells (PC-3).
A negative control with no conjugation of antibody is also shown.(14)

Figure 1-6. Silica nanoparticles uptake in Panc-1 cells which overexpress folate receptors and
HFF cells that have no folate receptor overexpression. (15)
7

1.4

Drug delivery in photodynamic therapy

Water solubility of a compound is very important when applying it to the biological
systems. Good water solubility can be obtained either by modifying the molecule or applying a
drug delivery system. Addition of Polyethyleneglycol (PEG) moieties or acids groups in the
structure of the compound can increase the solubility in the polar solvents such as water. For
drug delivery silica nanoparticles, liposomes, micelles are widely used due to their
biocompatibility and capability to functionalized with targeting structures.
Drug delivery systems based on polymeric particles (nanoparticles), micellar oildispersions, and liposomes have been studied and developed with varying degrees of success.
Researchers found oil based micellar drug using polyoxyethylated castor oil (Tween-80,
Cermophor-EL etc.) to enhance drug loading and tumor uptake, due to the interaction between
this micellar oil and the lipoproteins plasma in blood. However, some emulsifying agents elicit
acute hypersensibility reactions. Liposomal formations, can improve efficacy and safety of PS,
but are generally unable to establish elevated tumor to normal tissue ratio due to their short
plasma half-lives. However, there are some improvements to liposomal formulation reported
such as drugs combined inside pH-sensitive polymeric micelles which show an improvement in
tumor phototoxicity compared with Cremophor –EL in vitro, but in vivo studies represent poor
tumor regression and increase the accumulation in normal tissue.16, 17 All these techniques suffer
from free circulation and accumulation in skin and eyes and the patient become highly sensitive
to light.

8

Nanoparticles in photodynamic therapy
Birrench and Speiser are the first researcher that conceptualized nanoparticles18,
nanospheres and nanocapsules are an umbrella term with diameters less than 100 nm. Recently,
Interest in nanoparticles as drug delivery system (either dissolved in the matrix or adsorbed on
the surface of NPs) has increased due to the following: (a) nanoparticles can transport
hydrophobic drugs in blood, (b) they have large surface area that can be functionalized with
groups for additional chemical or biochemical properties, (c) nanoparticles have large volumes
of distribution and are taken up efficiently by cells; (d) possibility of drug release; and (e)
possibility of numerous synthetic strategies.19, 20 Currently, there are several researches who are
highlighted different approaches for utilizing nanoparticles for PDT. These approaches has been
categorized into passive and active nanoparticles depending on either absence or presence of any
targeting moieties on the surface or depending on their involvement in PS excitation.21

1.5

One photon and Two-photon Absorption Mechanism

Absorption of the photons causes excitation of the molecule to a higher energy electronic
state from the ground state. In one photon excitation, usually the molecule can be excited by one
photon that has similar energy with its energy gap between the highest occupied molecular
orbital and lowest unoccupied molecular orbital. However, when a molecule exposed to high
intensity of light undergoes near simultaneous absorption of two photons, the two photon
combined energy can also access a stable excited state of the molecule and this process is called
two-photons absorption (2PA).22 The demands for a spatial and temporal overlap of two incident
photons to undergo a 2PA generates precisely localized photoexcitation. For that reason, 2PA

9

has attracted significant attention for different kinds of applications such as photodynamic
therapy,23-25 bioimaging,26-28 3D data storage.29-31

1.6

One Photon and Two Photon Photodynamic Therapy

PDT compared with other methods has a number of advantages, such as minimally
invasive, low toxicity, rapid effect, and low cost. Additionally, PDT treatment can be repeated
without inducing resistance or hypersensitivity, which is considered a big problem associated
with chemotherapy. However, PDT still undergoes some challenges that limit its broader
application such as limited light penetration in tissue and the intense of incidence light can cause
tissue damage. In addition, since this process is oxygen dependent, the efficiency would be
difficult to increase in the hypoxic tumor system.32-34
The limitation of oxygen dependent efficiency can be solved by applying a new type of
PDT: photoacid generator (PAG) based PDT. The mechanism of PAG in PDT paradigm is to
induce cell death by causing an imbalance in the pH in the cell. This PAG can be excited with
one photon absorption (1PA) or two-photon absorption (2PA) and generate strong acid (Figure
1-7). It is hypothesized that this process can cause a fast drop in the pH of cell and induce cell
apoptosis or necrosis.25
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Leaky Tumor
Vasculature

Anoxic
Tumor Cell

Figure 1-7. One photon and two-photon absorption photoacid generator (PAG) based on PDT.
(25)

A 2PA photosensitizer, can be excited with longer wavelength NIR region. This provides
deeper penetration and less damage by incident light. Furthermore, 2PA has a quadratic
dependence on the intensity of light provided high spatial localization.35-37 1PA also has
advantage over the 2PA such as the simplicity of that associated with generating photoacid.
Furthermore, one photon photoacid generation is more affective process because the excitation
source needed for this process is cheaper and easier to use. Another advantage of 1PA is that a
large amount of targeted surface mass can be converted within tissue at a faster rate.
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1.7

Efficiency of photodynamic therapy

Singlet oxygen quantum yield measurement represents the efficiency of a photosensitizer
and shows the productivity of an excited photosensitizer to generate singlet oxygen. Some
Photosensitizers undergo fluorescence after excitation, which could be useful in the adjustment
of treatment fields.38 Photosensitizers with a higher fluorescence quantum yield will have lower
oxygen quantum yield. In this case, a balance is needed between fluorescence and singlet oxygen
generation for an effective photosensitizer.
Furthermore, an effective photosensitizer should have low cytotoxicity in the dark or else
healthy tissue will undergo cell death without PDT treatment. Another important consideration is
water solubility of photosensitizer so that it can function in biological systems. For clinical
treatment, a water-soluble agent can travel easily through the body.39 Delivery systems also
important and can be applied to carry the photosensitizer on the water.

1.8

Fluorene structure and properties
Structure Property Relation

Substitution pattern and different structures can classify compounds and lead to different
photophysical properties. So, the desirable properties can be achieved by structural design.
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Figure 1-8. Schematic of various linear compounds classified based on the substitution pattern.
(D= Donor group;  =  conjugated bridge; A = acceptor group). (40)

Usually, molecules with electron-rich groups located at the termini of the conjugated
bridge (Figure 1-8 I) exhibit an increased 2PA cross section with possibility that 2PA band can
also shift to a longer wavelength.40, 41
2PA cross section can also be larger when the electron withdrawing groups present in the
center of the  conjugated bridge (Figure 1-8 III).40 The extending of  conjugated bridge can
cause to an increase in 2PA cross section and a red shift of the 2PA maximum.41
Substitution of electron rich and poor groups at the opposite termini of a  conjugated
bridge (Figure 1-8 V) can cause a dipolar chromophore. Usually, dipolar chromophores have the
lowest energy 2PA band at the wavelength two times that of one photon absorption band.40
Increasing the length of conjugation can also cause increase in the 2PA cross section of dipolar
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molecules.42 The strength of substitution group can influence the 2PA cross section, a stronger
electron donor group is expected to yield a higher cross section compared with a weaker
substituent group.42, 43 Larger 2PA cross section are occasionally achieved when a triple bonds
are employed compared with double bonds.44, 45

Fluorene and Fluorene Derivatives
Fluorene cores has been mostly applied in both quadrupolar (Figure 1-8 I-IV) and
dipolar (Figure 1-8 V) causing large 2PA cross sections. Its planarity and rigidity (Figure 1-9)
induces large electron delocalization and serves as  conjugated bridge system.22, 45

9

2

7

4
Figure 1-9. Structure of Fluorene core

The core structure of fluorene can be functionalized in positions 2, 4, 7 and/ or 9
(Figure 1-9). When the substitution occurs at positions 2, 4, and 7 the conjugation length
increases resulting in high 2PA cross-section.22 Electron withdrawing or electron donating
groups can be substituted on these positions in order to obtain D--D, A--A or D--A
structures.27 Two fluorenes can also be used symmetrically in one structure, giving D--A--D
or A--D--A structures.26 Position 9 can also be functionalized to introduce alkyl chains or
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hydrophilic groups, to achieve solubility in organic solvent or water. The substitution at position
9 will not affect the photophysical properties of the conjugation system.22 Therefore; targeting
groups can be introduced at position 9 for selective delivery in biological application.42

1.9

Phosphate in urine as an indicator of potential cancer diseases

Determination of inorganic phosphate (Pi) in human urine plays an important role in
clinical diagnosis of various diseases. Phosphate levels in extracellular fluid accounts for about
1% of the total phosphate found in the human body, which is regulated by the parathyroid
hormone.46 Elevated levels of the parathyroid hormone are caused by hyperparathyroidism,
which can be diagnosed by abnormally high concentrations of phosphate in urine.46,

47

Both

conditions are associated with different cancer diseases such as bone, breast 48 and parathyroid.49
Furthermore, the concentration of phosphate is inversely related to the concentration of calcium
in urine, which can be associated with other diseases.46
A plethora of analytical methods have been developed for the analysis of inorganic
phosphate in human urine samples. These include photometric
chromatographic

52

50

, spectrophotometric

51

and ion

methods as well as fluorometric53 assays. Their analytical features are

summarized in Table 1-1.
Table 1-1. Analytical features of reported methodology for the analysis of phosphate in human
urine samples

Detection limit
(mmole L-1)

Sample
volume

Sample
preparation

Instrumental method

Interference

Analysis
time

Ref.

NA
0.02
NA
0.005

550 uL
10 mL
1 mL
50 uL

No
Centrifugation
No
No

Spectrophotometry
UV-vis Absorption
HPLC-UV-Detection
Fluorescence assay

Other anions
Ketones, albumin
No
Glucose

2 min
25 min
7 min
2h

50
51
52
53
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Although numerous approaches have been developed for the analysis of inorganic
phosphate in human urine samples, its determination at relevant biological concentrations via
rapid, cost effective and accurate methodology still remains a challenge. The need for sample
clean up and pre-concentration steps prior to quantitative analysis often leads to tedious and
time-consuming assays. As a tentative means of circumventing the shortcomings of classical
methodology, bio-sensing approaches coupled to amperometric54 and fluorescence55 detection
have been reported in the literature. Table1-2 provides a comparison of the two previously
reported sensors.

Table 1-2. Analytical features of sensing approaches for the analysis of phosphate ions in
human urine samples
Detection limit
(mmole L-1)

Sample
volume

Sample preparation

Sensor type

Interference

Analysis
time

Ref.

0.004

50 uL

No

CoPCSPCE1

Yes

5 min

54

NA

10 uL

Ultracentrifugation

Fluorescence

No

NA

55
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CHAPTER 2. DESIGN AND DEVELOPMENT OF NEW PHOTODYNAMIC CANCER
THERAPY AGENT SELECTIVELY INDUCES DEATH OF CANCER CELL

This chapter focuses on the design and development of new photodynamic therapy agent
photoacid generator (PAG) capable of inducing cell death of cancer cells making this agent an
ideal and formal therapeutic drug that can be used in vivo. This therapeutic agent generates acids
(H+ molecules) when excited with light at certain wavelengths; this causes a drop in pH within
the cytosol of the cancer cells, which then undergo necrosis. Since Silica nanoparticles (SiNPs)
have unique characteristic properties such as biocompatibility and capacity for functionalization
with groups for additional chemical or biochemical properties. They are promising tools for
biochemical investigation, providing solid media for drug delivery systems and high uptake
efficiency by cells. In addition, they are used as safe and biocompatible pharmaceutical
additives. Herein, we synthesized silica nanoparticles of ultra-small size (9 nm) covalently
bonded with the synthesized photoacid generator (SiN-NH-PAG) to enhance the solubility and
carry this hydrophobic agent in water as well as decrease the cytotoxicity. SiNPs provide a high
loading of functional groups (PAG) without dramatically affecting the structure while exploiting
SiNPs properties. On the other hand, we attached PAG with poly ethylene glycol (PAG-PEG) to
make it water-soluble in order to compare the results between these water-soluble moieties in
future studies. PAG was designed with high photoacid quantum yield and high one-photon (1PA)
and two-photon absorption (2PA) to enhance the penetration into optically thick tissue with low
fluorescence quantum yield.
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2.1

Introduction

Over the last 25 years, silica nanoparticles (SiNPs) and other nanomaterial, have attracted
tremendous interest from the scientific researchers due to their unique properties that differ from
those of their bulk counterparts such as large surface area, large pore volume, narrow
distribution, and excellent chemical and thermal stability making these nanoparticles potentially
suitable for various biomedical applications.56 SiNPs opens a new rout of applications in
optoelectronics and biological studies purposes.57 In controlled release applications, SiNPs has
shown high ability to store and release the therapeutic agents such as antibiotics.44 For drug
delivery system, SiNPs should be very selective, nontoxic, and show a good clearance rates.
Cornell dots (Cdots) are one of the SiNPs platform that meet all these criteria and has been
approved by FDA for human clinical trials suggesting SiNPs are a promising delivery system for
live animals.58
Synthesis of SiNPs has been done using variety of methods, Stober et al

59

in 1968,

reported a pioneering method for the synthesis of monodisperse SiNPs form aqueous alcohol
solutions of silicon alkoxides using ammonia as a catalyst and different sizes were prepared
ranging from 1 um to 50 nm with narrow size distribution. The size of particles depends on the
type of silicon alkoxide and alcohol. In methanol solutions, prepared particles are the smallest.
As the chain length of alcohol increases the particles size increases. The distribution of particles
sizes become broader, when longer chain of alcohol are used as a solvent. After that, many
studies were conducted in this area to prepare silica nanoparticles.
For biomedical applications, silica nanoparticles should be water soluble and hydrophilic
to prevent aggregation and precipitation in a biological environment. Photoacid generator
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(PAGs) are light sensitive compounds that generate acid when exposed to light at certain
wavelength, most photoacid generator absorb light in UV or Deep UV region and have several
applications such as coatings, paints, anticorrosives, photoresists, and microelectronics, and 2D/
3D lithographic patterning.60 Recently, our group successfully used PAG as new photodynamic
therapy agent inducing cell death of cancer cells (HCT-116).25
There were a lot of attempts to prepare triarylsulfonium salt in high yields. Although the
literature contains a number of synthetic procedures for the preparation of these compounds,
these procedures were deemed unsatisfactory for them due to their poor yields, high degree of
complexity, long reaction times, or general lack of applicability to a variety of substituted
symmetrical and unsymmetrical triarylsulfonium salts.61-63 Nesmeyanov and his co-workers

64

reported that arylation of diphenyl sulfide could occur by using diphenyliodoniumfluoroborate at
220-230 oC to yield triphenylsulfonium fluoroborate. When they used five times molar excess of
diphenyl sulfide, they got around 60% yield of the sulfonium salt.

(C6H5)2S + (C6H5)2I+BF4-

(C6H5)3S+BF4- + C6H5I

Knapcyzk and McEwen obtained a slightly better yield 64% when they repeat the
reaction for 35 h using 180 oC Temperature.65
James V. Crivello and Julia H. W.Lam

66

developed a new method for preparation of

pure triarylsulfonium salts in high yield (97%). They observed that diaryliodonium salts have
BF4-, AsF6-, and PF6 counterions which can undergo thermolytic decomposition at low
temperature 120 – 130 °C in the presence of catalytic amounts of a copper (II). In the absence of
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a copper (II) catalyst, these compounds can undergo decomposition near to their melting points
in the range 220-250 °C. Prior to that work, Beringer and his co-workers

67

reported that copper

(I) and (II) compounds catalyze the decomposition of diaryliodonium halides in solution. In
water or methanol, the major products were the aryl halides and the aryl iodide.
Ar2I+Cl-

ArI + ArCl

It was reported that the reaction undergoes concerted collapse of a complex formed
between the diaryliodonium ion and a di or trichlorocurate (I) ion. The same result were reported
with Glusker, and Roberts68 that the diaryliodonium tosylates and trifluoroacetates hydrolysis to
aryl halides and phenols is strongly catalyzed by traces of copper (I) and (II) which catalytic
activity was assigned to its ability work as an electron transfer agent.
Based on the above information and since the arylation of diphenyl sulfate using copper
(II) as a catalyst consumed long time to complete (conventional thermal conditions), our group
reported synthesis and characterization of novel sulfonium photoacid generators using micro –
assisted synthesis.60 This method afforded reaction times 90 to 420 times faster, resulting in
higher yield than conventional thermal conditions Table 2-1.
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Table 2-1. Microwave assisted Vs. Conventional thermal reaction time for Sulfonium salt PAG
formation.60
Product

MW Time (yield)

 Time (yield)

11

8 min (97%)

8 h (87%)

13

10 min (51%)

70 h (10%)

16

14 min (83%)

24 h (71%)

18

120 s (72%)

3 h (100%)

20

120 s (98%)

3 h (97%)
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90 s (88%)

3 h (83%)
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2.2

Materials and Methods

Compound (11) scheme 2-3 was synthesized as previously reported.69 Compound (7)
scheme 2-1 was synthesized as previously reported.60 All other chemicals and reagents were
purchased from Aldrich or Acros Organics, and used as received unless otherwise noted. 1H and
13

C NMR spectroscopic measurements were performed using Varian 400 or 500 NMR

spectrometers at 400 or 400 MHz for 1H (referenced to TMS at δ) (0.0 ppm) and 125 or 75 MHz
for
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C (referenced to CDCl3 at δ ) 77.0 ppm). All glassware was flamed dried and cooled in a

desicator over calcium chloride. Most of the reactions were carried out under N2 atmosphere. All
sulfonium salt reactions and purifications were carried out under red light, or in the dark.
Synthesis
Synthesis of Compound 1. Fluorine (6 g, 36.09 mmol) was dissolved in dry THF (150 mL)
under nitrogen gas and treated with n-BuLi (1.6 M in hexanes, 22.5 mL) at -78 °C drop by drop
over 30 min. After the addition complete, the temperature was raised to room temperature and
the mixture was stirred for 1 h. The mixture was cooled to -78 °C and a solution of ethylbromide
(2.6 mL) was added. The temperature was allowed to rise to room temperature and mixture was
left stirring for 24 h. The THF was evaporated from the orange solution in vacuum and then
extracted with CH2Cl2 yielding a yellow oil and purified by column chromatography using
hexane to give 6.4 g (91% yield). 1H NMR (400 MHz, CDCl3) δ 7.90 (d, 2H), 7.65 (d, 2H), 7.53
– 7.40 (m, 4H), 4.08 (t, 2H), 3.18 (d, J = 747.2 Hz, 1H), 0.89 (t, 3H).13C NMR (101 MHz,
CDCl3) δ 147.31, 141.44, 126.98, 126.90, 124.41, 119.98, 119.87, 119.86, 77.48, 77.16, 76.85,
48.59, 25.83, 9.87.
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Synthesis of compound 2. (6 g, 30 mmole) of compound 1 was dissolved in (28 mL) of dry pdioxane at 50 °C temperature and degassed under vacuum and nitrogen. After that 40% aqueous
solution of Triton B (0.25 mL) was added, the mixture color was changed from light yellow to
brown. This solution was then treated with acrylonitrile for 15 min. And the temperature was
maintained around 50 °C. The resulting brown solution was stirred for 16 h. after which it was
neutralized with 10% HCl (aq) and extracted with CH2Cl2. The crude product was purified by
column chromatography using 5:1 hexane/ethyl acetate to afford white solid (5.9 g mmole (77%
yield) mp = 99.2-100 °C. 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 1.1 Hz, 2H), 7.34 (dd, J =
3.6, 1.1 Hz, 6H), 2.41 (m, 2H), 2.03 (t, 2H), 1.49 (t, J = 4.0 Hz, 2H), 0.31 (t, 3H). 13C NMR (101
MHz, CDCl3) δ 147.26, 141.43, 127.92, 127.81, 127.64, 122.83, 120.22, 119.88, 77.48, 77.16,
76.84, 54.87, 35.65, 32.85, 12.27, 8.30.

Synthesis of Compound 3. (4 g, 17.1 mmole) of compound 2 was dissolved in ethylene glycol
(150 mL). (4 M, 50 mL) of KOH was added and heated to reflux for 16 h. After that, ethylene
glycol was removed by vacuum distillation to afford yellow oil which was neutralized with 10%
HCl (aq) and CH2Cl2 was used for extraction. The crude product purified by column
chromatography hexane/ethyl acetate (3:1) to produce (3.65 g) (85 % yield) mp = 134.8-135 °C.
1

H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 6.7 Hz, 2H), 7.44 – 7.17 (m, 6H), 2.56 – 2.24 (m,

2H), 2.06 (q, J = 7.3 Hz, 2H), 1.68 – 1.49 (m, 2H), 0.34 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz,
CDCl3) δ 179.81, 148.45, 141.35, 127.35, 127.35, 127.30, 122.82, 122.82, 119.87, 77.33, 77.02,
76.70, 54.65, 34.25, 32.96, 28.92, 8.31.
Synthesis of Compound 4. (3 g, 11.9 mmole) of compound 3 was dissolved in glacial acetic
acid (25 mL). The resulting solution was heated to 55 °C and (2 mL) of 70% Nitric acid was
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added drop wise. After the addition was complete, the mixture was stirred for 3 h and monitored
by TLC. The reaction was stopped by adding 10 mL water and extracted with CH 2Cl2. The
afforded yellow oil was purified by column chromatography 3:1 hexane/ethyl acetate to give
yellow solid (2.8 g,) (79% yield). mp = 134.8-136 °C. 1H NMR (400 MHz, CDCl3) δ 8.50 – 8.17
(m, 2H), 7.92 – 7.76 (m, 2H), 7.59 – 7.40 (m, 3H), 2.64 – 2.33 (m, 2H), 2.26 – 2.03 (m, 2H),
1.79 – 1.45 (m, 2H), 0.34 (t, J = 7.4 Hz, 3H).
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C NMR (101 MHz, CDCl3) δ 179.39, 150.13,

149.79, 147.82, 147.25, 139.00, 129.63, 128.03, 123.81, 123.29, 121.46, 120.07, 118.50, 77.39,
77.07, 76.75, 55.35, 33.87, 32.72, 28.90, 8.25.

Synthesis of Compound 5. (2 g, 6.7 mmole) of compound 4 was dissolved in (30 mL) glacial
acetic acid and placed into three neck flask fitted with condenser, nitrogen gas and thermometer.
The mixture was degassed with nitrogen for 15 min. then I2 (850 mg, 3.3 mmole) was added and
the resulting orange solution was stirred for 30 min. After that, (924 mg, 13.4 mmole) of NaNO2
followed by concentrated H2SO4 (1.5 mL) was added and the reaction heated to 125 C° and
monitored by TLC for 3 h. After the reaction had completed, the reaction was cooled down and
extracted with ethyl acetate and the resulting yellow oil was purified by column chromatography
using 3:1 hexane/ ethyl acetate to give a yellow solid ( 2.52 g) (90% yield), mp = 181-182 °C.
1

H NMR (400 MHz, CDCl3) δ 8.28 (d, J = 8.4, 2.1 Hz, 1H), 8.20 (s, J = 3.2 Hz, 1H), 7.86 – 7.73

(m, 3H), 7.54 (d, J = 8.6 Hz, 1H), 2.60 – 2.33 (m, 2H), 2.24 – 1.97 (m, 2H), 1.74 – 1.47 (m, 2H),
0.33 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 179.58, 152.56, 149.59, 147.98, 147.08,
138.95, 137.59, 133.01, 124.29, 123.26, 120.65, 118.89, 96.15, 77.73, 77.41, 77.09, 55.93, 34.06,
32.98, 29.27, 8.60.
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Synthesis of Compound 8. In 2 mL of dry DMF (500 mg, 1.18 mmole) of compound 5 and
(200 mg, 0.94 mmole ) of compound 7 (phenyl (4-vinylphenyl) sulfane) were dissolved with
0.01g, (10% molar) of Palladium acetate, and (1.7 mL) of triethylamine. The resulting brown
solution was purged with nitrogen for 10 min. while stirred. The microwave was adjusted to
closed vessel standard mode; maximum temperature 160 °C; maximum pressure 250 psi;
maximum power 60 W, and high speed stirring. The run time (a time at which the reaction
approaches maximum temperature or pressure) was adjusted for 2 min. and the hold time 30 min.
the reaction was monitored by TLC. After starting material was gone, the mixture cooled down
and celite plug was used to filter it. The filtrate was extracted with CH2Cl2 and washed with
water 4x, dried with anhydrous magnesium sulfate and concentrated to afford brown oil which
was purified by column chromatography using hexane/ethyl acetate (2:1) to give a yellow crystal
(485mg) (99%). Mp = 81-82 °C. 1H NMR (400 MHz, CDCl3) δ 8.29 (d, J = 8.4, 2.1 Hz, 1H),
8.22 (s, J = 1.8 Hz, 1H), 7.79 (q, J = 8.1, 6.1 Hz, 2H), 7.42 (m, J = 14.4, 13.5, 9.2, 7.6, 3.5 Hz,
11H), 7.18 (s, 2H), 2.46 (m, J = 8.2 Hz, 2H), 2.24 – 2.10 (m, 2H), 1.62 (t, J = 13.2 Hz, 2H), 0.37
(t, J = 7.3 Hz, 3H).
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C NMR (101 MHz, CDCl3) δ 178.16, 150.76, 149.98, 147.45, 147.12,

138.77, 138.59, 135.95, 135.68, 135.19, 131.49, 131.45, 130.80, 129.31, 129.06, 128.50, 127.38,
127.30, 126.78, 123.94, 121.73, 120.96, 119.97, 118.46, 77.33, 77.22, 77.01, 76.70, 55.33, 33.93,
32.82, 28.73, 8.30.

Synthesis of Compound PAG9. (370 mg, 0.7101 mmole) of compound 8 was dissolved in (2
mL) of chlorobenzene in a (2 mL) glass reaction vessel, 302.8 mg, (0.711 mmole) of
diphenyliodonium hexafluoro phosphate and 0.005 g (5% molar) of copper (II) benzoate were
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mixed in the dark while purged with nitrogen for 10 min. while the microwave was adjusted to
closed vessel standard mode; maximum temperature 125 °C, maximum pressure 40 psi;
maximum power 100 W, high seeped stirring. The run time (the time at which the reaction
approaches max temperature or pressure) was set for 1 min. and the hold time 15 min. TLC was
used to monitor the reaction every 2 min. upon the completion the solvent was evaporated to
produce a brown crude product. The resulting crude was purified by column chromatography
using DCM/Methanol 9:1 to afford a yellow solid crystal (470 mg ) (87%) mp = 63-64 °C. 1H
NMR (400 MHz, DMSO) δ 8.28 (s, J = 2.9 Hz, 1H), 8.25 (d, J = 2.0 Hz, 1H), 8.15 – 7.97 (m,
4H), 7.93 – 7.75 (m, 14H), 7.66 (d, J = 16.3 Hz, 1H), 7.57 (d, J = 16.4 Hz, 1H), 2.19 (m, J =
30.8, 14.6, 7.7 Hz, 4H), 1.49 – 1.08 (m, 2H), 0.23 (t, J = 7.3 Hz, 3H).13C NMR (101 MHz,
DMSO) δ 175.81, 152.84, 152.07, 147.67, 143.97, 139.85, 138.24, 135.08, 134.23, 132.65,
132.15, 131.98, 129.64, 128.02, 127.73, 126.26, 124.24, 123.31, 122.85, 122.30, 121.48, 119.12,
116.14, 56.32, 36.17, 32.17, 9.11.

Synthesis of Compound PAG-PEG. Benzotriazole (64 mg, 0.005 mmole) was dissolved in (10
mL) dry DCM in 25 mL round bottom flask while it was purged with nitrogen and stirred at
room temperature until the solution became clear. After that 0.1 mL of thionyl chloride was
added. After the addition had completed, the solution was treated with (100 mg, 0.13 mmole,) of
compound PAG 9 and the reaction was stirred for another 2 h. Then, 1 equivalent mmole of
polyethylenglycole (PEG) was added and stirred for 3 h. the DCM was evaporated to give crude
dark yellow oil. The afford crude was purified by column chromatography 5:1 DCM/ Methanol
to produce brown oil (165 mg), (70% yield). 1H NMR (400 MHz, MeOD) δ 8.29 – 8.13 (m, 2H),
7.91 (dd, J = 18.5, 9.2 Hz, 4H), 7.80 – 7.61 (m, 14H), 7.51 (d, J = 10.1 Hz, 1H), 7.27 (d, J = 4.4
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Hz, 1H), 3.76 – 3.15 (m, 96H), 2.51 – 2.33 (m, 2H), 2.20 – 2.00 (m, 2H), 1.39 (dd, J = 17.1, 9.1
Hz, 2H), 0.22 (t, J = 6.0 Hz, 3H).13C NMR (101 MHz, MeOD) δ 174.10, 151.58, 151.00, 147.80,
147.64, 144.50, 140.17, 138.15, 134.77, 134.02, 131.88, 131.71, 131.15, 129.33, 127.71, 126.96,
125.54, 123.77, 122.38, 122.10, 121.95, 120.56, 118.72, 71.89, 70.46, 70.41, 70.34, 70.27, 70.07,
69.24, 58.03, 55.97, 48.64, 48.57, 48.43, 48.36, 48.22, 48.15, 48.00, 47.93, 47.72, 47.51, 47.29,
39.20, 34.76, 32.69, 30.71, 7.58.

Synthesis of Compound PAG-NH-Boc. Synthesis of PAG-NH-Boc compound was performed
using the same procedure for compound (PAG-PEG). 1H NMR (400 MHz, MeOD) δ 8.38, 8.32,
8.30, 8.26, 8.14, 8.12, 8.12, 8.10, 8.09, 8.07, 8.06, 8.05, 8.04, 8.03, 7.89, 7.88, 7.86, 7.84, 7.83,
7.81, 7.77, 7.75, 7.70, 7.66, 7.61, 7.57, 7.47, 6.87, 6.75, 6.72, 3.38, 2.81, 2.52, 2.51, 2.26, 2.17,
2.14, 1.34, 1.20, 1.07, 0.24, 0.23, 0.22. 13C NMR (101 MHz, MeOD) δ 172.63, 157.11, 153.11,
152.31, 148.59, 144.71, 140.70, 139.17, 135.91, 134.98, 133.48, 132.96, 132.77, 130.85, 130.44,
128.63, 127.04, 125.22, 124.19, 123.19, 122.42, 120.17, 116.89, 78.89, 57.01, 56.50, 35.78,
33.23, 31.65, 29.83, 28.51, 27.91, 9.83.

Synthesis of Amine-Terminated Silica Nanoparticles (SiNPs). Synthesis of (SiNPs) was
performed following the method described by P.N. Prasad et al. with some modifications.70 The
synthesized silica nanoparticles and their bioconjugates with PAG 9 were schematically
described by Scheme 2-2. Briefly, the nanoparticles were synthesized by adding polymeric
organically modified silica solution into the Tween-80/ 1-butanol micelle solution dissolved in
deionized water. First, 0.5 g of Triethoxyvinylsilane (VTES, 97%) was dissolved in 5 mL of Nmethyl-2-pyrrolidone (NMP) and condensed in the presence of 200 μL of ammonium hydroxide
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(28–30%) at room temperature with 16 h stirring in order to get a clear solution of
prepolymerized silica solution. After that, the prepolymerized silica solution was filtered using a
membrane filter (0.2 μm pore size). Micelles were prepared by mixing 0.1 g of Tween-80 and
0.2 mL of 1-butanol in 5 mL of deionized water.
100 μL of silica solution was mixed with 0.2 mL of NMP and then added to the prepared
micelle dispersions drop by drop to induce nanoprecipitation under vigorous stirring. After 10
min, 20 μL of (3-aminopropyl)triethoxysilane (APTES) was added in order to functionalize the
surface of SiNPs. The mixture was stirred for further 24 h in order to be sure the sol-gel
condensation within the coprercipitation nanoparticles was complete. Purification of
nanoparticles was performed by dialyzing the dispersion against deionized water in a 10 KDa
cutoff cellulose membrane to remove Tween-80 and 1-butanol for 48 h. The solution was then
filtered with a 0.2 μm cutoff membrane filter.

Conjugation of amine-terminated silica nanoparticles with PAG 9
A 0.2 mL of 0.1 M EDC solution was added to a 5 mL of stock solution of amineterminated silica nanoparticles. After the mixture was stirred for 25 min, an excess of PAG 9
(3.5mg) was added. The reaction between amine groups with PAG was allowed to proceed for 3
h. After that, the reaction mixture was dialyzed against deionized water in the dark for 48 h in
order to remove unreacted molecules. Finally, the sample was filtered with a 0.2 μM cutoff
membrane filter and stored at 5 0C for later use.
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2.3

Particle Size

Particle size data was obtained with a Zetasizer Nano ZS90, using Silica nanoparticles
capped with amino group solution and Silica nanoparticles covalently bonded with PAG
solution. Both of solutions were filtered with 0.2 m polyethersulfone membrane filters with
polypropylene housing.
2.4

Photophysical Characterizations
Absorption spectra

Absorption spectra were recorded by using Agilent 8453UV-vis spectrophotometer.
Steady state fluorescence spectra were measured by EDINBURGH INSTRUMENTS FLS980
spectrofluorimeter.
Fluorescence Quantum Yield Measurement
Relative to Rhodamin 6G (Rh6G) in ethanol as a standard, fluorescence quantum yield
was determined. The measurement was made in the photon-counting regime of a PMT by using
an L-format configuration using EDINBURGH INSTRUMENTS FLS980 spectrofluormiter. The
measurement was performed at room temperature in 1 cm quartz cuvettes with concentration 1
×10-6 M. Using the following equation
𝑂𝐷𝑟𝑒𝑓 ∫ 𝐼
𝑛2
𝜙 = 𝜙𝑟𝑒𝑓 (
)(
)( 2 )
𝑂𝐷
∫ 𝐼 𝑟𝑒𝑓 𝑛𝑟𝑒𝑓
where Ф is the fluorescence quantum yield, OD is the optical density at the excitation
wavelength, I is the integrated fluorescence intensity, and n is the refractive index of the solvent.
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Two-Photon (2PA) Cross Section Measurement

The investigations of the 2PA were performed with a femtosecond laser system
(Coherent, Inc.). The output of a Ti:Sapphire laser (Mira 900-F, tuned to 800 nm, with a
repetition rate = 76 MHz, average power ~1.1 W, and pulse duration ~200 fs), pumped by the
second harmonic of cw Nd3+:YAG laser (Verdi-10), was regeneratively amplified with a 1 kHz
repetition rate (Legend Elite USP) providing ∼100 fs pulses (FWHM) with energy ∼3.6
mJ/pulse. This output at 800 nm was split into two separate beams with average power ∼1.8 W
each and pumped into two ultrafast optical parametric amplifiers (OPerA Solo (OPA), Coherent
Inc.) with a tuning range 0.24−20 μm, ∼100 fs (FWHM), and pulse energies up to ∼100 μJ. A
single laser beam from the first OPA was used for direct 2PA cross-section measurements by the
open-aperture Z-scan method.71

Photoacid Quantum yield Measurement
Photoacid quantum yield was measured by selectively exciting the PAG solution at the
suitable wavelength using LOCTITE. The power of the incident light was measured by using
Ophir Power Star power meter, which was equipped with a UV

1.44 cm2 detector head. To

calculate the quantum yield Rhodamine B base was used as a sensor for the photoacid generator,
and observed the change on the optical density of sulfonium salt with not exceed 5%. The
quantum yield for photoacid generator was calculated by using the following equation:

∅𝐻 =

∆𝑂𝐷555 . 𝑁𝐴
103 .

𝑅ℎ𝐵
𝜀555

. 𝐼𝑜 . [1 − 10−𝐷̅ ]. ∆𝑡

30

Where D555 is the change in the optical density during the generation of Rhodamine B
𝑅ℎ𝐵
measured at 555nm, NA is the Avogadro number, 𝜀555
is the extinction coefficient of

̅ is the average absorption intensity, 𝐼𝑜 is the Intensity of irradiation
rhodamine B at 555 nm, 𝐷
(photon/cm2.sec), and ∆𝑡 is the time of irradiation in sec.

2.5

Results and Discussion
Synthesis

The synthesis of triarylsulfonium salts was originally developed by Crivello and Lam.
They used a new method for the preparation of pure triarylsulfonium salts with high yield and
less time consumption by using a copper (II) benzoate as a catalyst for the reaction.62 Although
there are a lot of synthetic procedures for the preparation of these compounds, these methods
were unsatisfactory due to their low yields, reaction taking long time, and complexity. Recently,
a microwave-assisted synthetic route has been reported, which is more efficient in preparing
triarylsulfonium salts.60
Most of commercially (PAGs) available needed ultraviolet (UV) light to achieve his job
and this is considerate a major problem since the UV light is a sort of non-selective excitation
that maybe caused undesirable side reaction, and offers poor penetration. In order to make PAG
more efficient, we designed and synthesized a new PAG that absorbs light at a long wavelength
(VIS region), which on utilizing 1PA and 2PA the molecule demonstrates enhance penetration.
The synthesis of photoacid generators PAG-PEG, and SiN-NH-PAG are illustrated in scheme21, scheme2-2, and scheme 2-3. The synthesis scheme 2-1 started with asymmetric alkylation at
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position 9 of fluorene with ethyl and acrylonitrile groups to get intermediate compound 2. Next,
intermediate compound 3 was synthesized by hydrolysis of intermediate compound 2 in basic
conditions using aqueous solution of sodium hydroxide in the presence of ethylene glycol and
refluxed for 24 hours to get a carboxylic group for further conjugation. Intermediate compound 4
was synthesized by introducing a nitro group at position 2 of fluorene using HNO3 (70%) acetic
acid as a solvent. An iodo group was also introduced at position 7 of fluorene to produce
intermediate compound 5. On the other branch of synthesis, we synthesized intermediate
compound 6 starting from p-nitrobenzaldyhade with thiophenol using caesium carbonate reagent
in DMSO. Intermediate compound 7 was synthesized according to literature with some
modification. Intermediate compound 8 was obtained quantitatively via a microwave-assisted
palladium acetate-catalyzed Heck reaction, coupling vinyl sulfide 7 with precursor 5 and the
yield for this reaction was 99%. Next, PAG compound 9 was synthesized by pyrolysis of
diphenyliodonium counterpart in the presence of diphenylsulfide (intermediate compound 8)
using microwave-assisted synthesis to give 89% yield. Then, intermediate compound PAG9 was
coupled with polyethyelenegycol (PAG-PEG) Scheme 2-1, and silica nanoparticles (SiN-NHPAG) Scheme 2-2, for different water-soluble derivatives. PAG was also conjugated with Tertbutyl (4-aminobutyl)carbamate to produce PAG-NH-Boc for future study as shown in
scheme 2-3.
The synthesis and surface modification of silica nanoparticles are schematically described
in Scheme 2-2. A prepolymerized triethoxyvinylsilane (VTES) sol solution was first prepared.
After that, the sol solution was mixed and corecipitated within the nonpolar aqueous Tween-80
micelles by a solvent displacement process. (APTES) was added to the reaction mixture in order
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to introduce free amine groups on the silica nanoparticles surface for subsequent bioconjugation.
Conjugation of amine –terminated silica nanoparticles with PAG 9 was done using EDC
coupling reagent and an excess of PAG 9 was added to be sure there is no free amine in the
surface of silica nanoparticles.
The PAG was designed to exhibit high 1PA, 2PA cross-section and photoacid quantum
yield. Fluorene was selected as a core structure due to high thermal and photochemical stability
and the capability of substitution on the position 2-, 7-, and 9. Stilbenyl motifs were introduced
in order to extend the π-conjugation and two acceptor groups (nitro and triarylsulfonium) were
attached to get net structure of A-π-π-A . Nitro group was introduced in the structure in order to
enhance the photoacid quantum yield by increasing the chance of spin orbit coupling to make
intersystem crossing and reducing the radiative decay pathway. As a result decrease the
fluorescence quantum yield. In case of PAG with high fluorescence quantum yield, the molecule
will undergo radiative decay (fluorescence) before forming photoacid.25
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Scheme 2-1. Synthesis of water-soluble photoacid generator bonded with polyetheylengylcol
(PAG-PEG).
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Scheme 2-2. Silica nanoparticles conjugated with photoacid generator (SiN-NH-PAG).

Scheme 2-3. Design and synthesis PAG-NH-Boc.
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Photophysical Characterization
2.5.2.1 Absorption and Fluorescence Emission Spectroscopy

The photophysical properties of (PAG 9) and PAG-PEG compounds were examined by
UV-vis absorption and fluorescence emission spectroscopy. The measurements of absorption and
fluorescence emission were carried out in different solvents DCM, MeOH, and ACN and it
showed no difference in the absorption and emission bands. Figure 2-1 and Figure 2-2, show
the UV-vis and fluorecsnce emission of PAG 9 in DCM and PAG-PEG in water respectively.
Both of them are showing maximum wavelength of absorption about 385 nm and emission
around 520 nm.
Fluorescence quantum yields of PAG 9 and PAG-PEG were also investigated. As shown
in the Table 2-2, both of them exhibited low fluorescent quantum yield of approximately 0.02.

Figure 2-1. UV-vis absorption (blue line) and fluorescence emission (red line) spectra of PAG 9
in DCM.
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Figure 2-2. UV-vis absorption (black line) and fluorescence emission (red line) spectra of PAG PEG in water.

Table 2-2. Photophysical Properties of PAGs
PAG
PAG 9
PAG-PEG
SiN-NH-PAG

 ab (nm)
384  2
387 3
384  2

 em (nm)
522  2
513  2
533  3

F
0.04  0.03
0.02  0.01
0.08  0.03

H+
0.41  0.02
0.39  0.04
-----

F Fluorescence quantum yield of PAG 9 in DCM and PAG-PEG, SiN-NH-PAG in water with diphenylanthracene
in cyclohexane as the standard, H+ photoacid quantum yield at 366 nm with rhodamine B base

Two-Photon Properties
Two-photon absorption measurement was also obtained using femtosecond laser system
(Coherent, Inc.). Since all of synthesized PAGs have the same system A-π-π-A, PAG-PEG was
selected for 2PA cross-section investigation. The 2PA spectra were recorded in DCM at room
temperature using open aperture z-scan measurements. The results showed PAG-PEG has a 2PA
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cross-section (δ2PA) around 120 GM as shown in Figure 2-3, and Table 2-3. This gives a good
promising result for using them as a 2PA photodynamic therapy agent.
Table 2-3. Two-photon absorption of PAG-PEG properties

Solvent

DCM

λAbs (nm)

385 ± 1

λEm (nm)

513 ± 1

ΦFL

0.02 ± 0.002

δ2PA (GM)

120

2PA Wavelength (nm)
600

800

1000

1200
1PA
2PA

1.0

120
0.8
90
0.6

60

0.4

2PA (GM)

Normalized Absorption

1400
150

30

0.2

0.0
300

400

500

600

0
700

1PA Wavelength (nm)

Figure 2-3. One-Photon Absorption (1PA) in DCM (black line), and two-photon absorption
(2PA) in DCM (green line) spectra for PAG-PEG.
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Calculation of Photoacid Generator Quantum Yield

Photoacid generator quantum yield was measured by using rhodamine B base as sensor in
DCM. Rhodamine B base represents a closed-ring structure as shown in Figure 2-4, when
protonated from an acid the close ring opens yielding rhodamine B.

Figure 2-4. Rhodamine B base and rhodamine b structures.

Rhodamine B base has no absorption peak in the area 550 nm; when protonated the
absorption peak at 550 nm will increase gradually. Based on Figure 2-4, we measured the
photoacid quantum yield using rhodamine B base as an indicator. PAGs at concentration of 10-4
M were mixed with rhodamine B base at concentration 10-5 M and illuminated for different time
intervals as shown in Figure 2-5. The PAG 9, PAG-PEG exhibited high photoacid quantum
yields of about 0.4 as shown in Table 2-2
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A

B

Figure 2-5. (A) Absorption spectra of 10-4 M concentration of PAG 9 mixed with 10-5 M
concentration of RhB base as indicator using 87 μW @ 366 power light, (B) 10-4 M
concentration PAG-PEG mixed with 10-5 concentration of RhB base as indicator, using 92 μW
@ 366 nm power light for irradiation with different times.
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2.6

Characterization of Silica Nanoparticles
UV-vis Characterization

Silica nanoparticles dispersed in water solution were characterized by measuring UV-Vis
spectra using Agilent 8453UV-vis spectrophotometer as shown in (Figure 2-6 A, B); it is
clearly indicated that the absorbance peak at abs 384 nm is related to PAG.

B

A

Figure 2-6. A- Absorption spectra of surface modified SiNPs Capped with amine groups, BAbsorption spectra of surface modified SiNPs covalently bonded with PAG 9 via amid links
dispersed in water, abs 384 nm.

Particles Size
Silica nanoparticles sizes and zeta potential were measured with a Zetasizer Nano system
and the results compared to that before and after coupling with PAG 9.

Size of silica

nanoparticles capped with amine groups before coupling was (4 nm), after being covalently
bonded with PAG 9 via amid links became (9 nm), while the zeta potential did not show any
significant different before and after coupling as shown in Table 2-4 and (Figure 2-7).
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Table 2-4. Particle size and zeta potential of silica nanoparticles functionalized with amino
groups before and after coupling with PAG 9.

Particle size
SiN-NH2

Particle size
SiN-NH-PAG

4 nm

9 nm

SiN-NH2

SiN-NH-PAG

Figure 2-7. Silica Nanoparticles size Functionalized with Amine Groups before and after
coupling with PAG 9 using Zetasizer Nano system.
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1

HNMR Characterization

Further characterization was done using 1HNMR and the results indicate an obvious PAG
peak at 7.69 ppm as shown in Figure 2-8 B.

A

B

PAG

Figure 2-8. A- 1H-NMR for Silica nanoparticles functionalized with amine (SiN-NH2), B1
HNMR for Silica nanoparticles covalently bonded with PAG (SiN-NH-PAG) in D2O.
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2.7

Conclusions

Design and development of new photodynamic therapy agent (PAG) is reported here.
PAG was conjugated first with polyethylenegylcole (PEG) polymer PAG-PEG. Second PAG
was covalently bonded with synthesized ultra-small size silica nanoparticles surface modified
with amine groups to get a formal and ideal agent for photodynamic therapy treatment that can
be injected in vivo. These water-soluble derivatives were fully characterized using 1HNMR and
13

C and mass spectroscopy. In addition, photophysical properties were also measured. Generally

PAG fluorescence quantum yield is around 0.0  0.02 while photoacid quantum yield is around
0.41  0.02. A 2PA cross-section for PAG was also measured and found to be around 120 GM.
These results encourage us to test them (water soluble agents) in the HCT-116 cells and compare
the results in chapter 3.
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CHAPTER 3. TESTING AND MONITORING OF THE NEW PHOTODYNAMIC
CANCER THEARPY AGENT WITH HUMAN COLORECTAL CARCINOMA
(HCT-116) CELL

Photodynamic therapy (PDT) processes with singlet oxygen sensitizers are facing a lot of
difficulties and complexities since they rely heavily on the concentration of oxygen present in the
tissue to be treated. Most cancer lesions have low levels of oxygen (hypoxic) because of the poor
vasculature of these regions. As a result, these hypoxic cells have a resistance to death by
irradiation using photosensitizer compounds. Herein, we test new photodynamic therapy (PDT)
agents, such as an oxygen-independent agent sulfonium salts (photoacid generator) that cause a
pH drop within cancer cells by generation of acid within cytosol.
Two different water-soluble photoacid generators (PAG) have been tested using
HCT-116 cell line and the results compared. First, PAG was connected with ≈ 23 units of
polyethylene glycol (PEG) groups PAG-PEG to produce a highly water solubility and low
cytotoxicity compound. Second, PAG was conjugated with highly monodispersed silica
nanoparticles ultra-small size functionalized with amine groups via amid links. Each particle has
an average size of 9 nm with PAG monomers attached to the surface of each particle. PAG
covalently incorporated within the delivery vehicles and is anticipated to solve the drawback of
their premature release, thus enhancing the results of PDT. The PDT processes were completed
using one photon absorption (1PA) of endocytosed photoacid generator (PAG) and the results
indicated that silica nanoparticles with PAG (SiN-NH-PAG) induced cell death more than (PAGPEG). The increased effectiveness of the nanoparticles is assumed to be because of the large
number of PAG groups present on the nanoparticles. Which results in a greater number of PAGs
present per unit volume of substrate, compared to the single molecule species. The drop in the
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pH in the Lysosome was measured around 0.3 units (approximately pH ≤ 4.4) inside the
lysosomes and this is undoubtedly a good event as most cells underwent necrosis. Cells were
imaged with confocal microscope (Olympus IX-81) at 1 min interval for 4 hours by using DIC
channel.

3.1

Introduction

Photodynamic therapy (PDT) has been established as a cancer treatment which employs
light sensitive nontoxic compounds that when irradiated with light at a specific wavelength
results toxifying of the target area, namely malignant and diseased cells and tissue.72 PDT has
been known for hundred years, but only at the end of the nineteenth century did it became widely
used and utilized. Usually the first component is a photosensitive compound (photosensitizer)
that localizes to target cell. The second component is light of specific wavelength to activate the
sensitizer. When the photosensitizer is promoted to an excited state in the presence of oxygen, it
will transfer energy from the light to the oxygen to generate singlet oxygen. The reactive oxygen
species will attack any organic compounds and are highly cytotoxic.73 Photodynamic therapy
with photosensitizer compounds has a lot of problems because of the low oxygen concentration
in the cancer cells (hypoxic). In order to make it successfully work with photosensitizer, we need
to carefully balance three important factors and these factors should be presented at the time of
therapy: Oxygen saturation of the tissue (the most important condition), the photosensitizer
concentration should be enough throughout the lesion, and enough intensity of light should be
available. All these conditions are present in heterogeneous concentrations and doses even in a
single gland like the prostate. This makes the process difficult and compromised the production
of singlet oxygen photosensitized.74,75.
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A challenge that PDT has for a considerable period of time is the production of singlet
oxygen in an oxygen-depleted environment. Healthy tissues have very well structured vessels
and the inner walls are conformed by well-differentiated endothelial cells. On the other hands,
the tumor vessels have poor morphology conformed by immature cells in a mesh like
construction, which give a leaky character to the vessel. This leaky property related to these
vessels, produce a hypoxic and acidic environment.76 Since the hypoxic environment has a
limited amount of oxygen to be excited, this leads to poor outcomes in the production of singlet
oxygen. Furthermore, this will lead to ischemia, a malady which compromises the flow of
oxygen to the tumor and hinders complementary chemotherapeutic agent delivery via the
bloodstream.75,77
Since nanomaterials have biological and chemical flexibility, nontoxic, and
multimodality of the surface, they become revolutionized the fields of medicine (in both
diagnosis and therapy), bioimaging, and photonics.78-80 Recently, nanomaterials have been
widely used in the application of gene delivery as DNA carriers,81 photodynamic therapy
carrying the photosensitizer,82,
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and bioimaiging nanopropes.70,84 Most of the PAGs have

hydrophobic nature, for that reason, we trying to develop an ideal photoacid generator
formulation that can be easily used and injected in vivo. Recently, many methods have been
reported to achieve stable aqueous dispersion as well as site-specific and time controlled delivery
of the therapeutic agents by using a delivery vehicle.
Because drugs are not a prerequisite for their therapeutic action in PDT,85 covalently
incorporating the PAG within the delivery vehicles is anticipated to solve the drawback of their
premature release thus enhancing the results of PDT.
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Herein, we test new photodynamic therapeutic agents (photoacid generator, PAG) Figure
1-3. These afforded oxygen-independent PDT by inducing imbalance of the pH within the
cytosol of the cells that were targeted instead of inducing cell death by singlet oxygen from
photosensitization, also constructed a molecule with a greater extinction coefficient for 1PA and
a greater 2PA absorption cross section. In both cases we tailored the molecule to absorb at longer
wavelengths, which promotes deeper penetration of therapy. Also hydrophilic PAG 9 was
conjugated with silica nanoparticles and polyethylene glycol (PEG) group ≈ 23 units making it
highly water-soluble and low cytotoxicity. We synthesized silica nanoparticles that consist of a
highly aqueous stable design of organically functionalized amine groups covalently bonded with
PAG molecules via amid link with ultralow size (9 nm). These nanoparticles are well suited for
in vivo experiments when compared with larger sizes. These results in a highly monodispersed,
and stable species in aqueous solution making theme able to generate acid molecules during the
photoactivation and treat the cancer.

Figure 3-1. Hydrophilic PAGs (SiN-NH-PAG), and (PAG-PEG).
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3.2

Materials and Methods
Cell Culture

Cells HCT-116 (ATCC, USA) were cultured in RPMI-1640 medium, supplemented with
10% FBS, 1% penicillin-streptomycin, at 37 C in a 95% humidified atmosphere containing 5%
CO2. Cells were splitted every two days when they reach 70-90% confluency. Briefly, soaking
all medium from the plate then 2 ml of Trypsin was added (to detach the cells from the bottom of
the plate) and put it back in incubator. After 10 min., (8 ml) of fresh medium was added and the
solution was centrifuged for 5 min at 1000 rpm speed. The old medium was removed and (10 ml)
of fresh medium was added and then split in a new plate and incubated again.

Cell Counting (Hemocytometer)
Cells were counted using chamber called a Hemocytometer. A Hemocytometer contains
a thick glass microscope slide with a grid (perpendicular lines scraped in the middle). In this
grid, there are specific dimensions so the area covered by the lines is known and counting
number of cells in specific volume of solution becomes possible.
A coverslip was placed over the counting surface and then cell suspensions were loaded
(20ul) a using pipette tip into one of V-shaped wells as shown in Figure 3-2. Then, the loaded
Hemocyometer was placed on microscope stage and cells were counted.
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20 ul Loading of Hemocytomer

Figure 3-2. Loading the Hemocytometer
The Hemocytometer grid contains nine squares, each of them is 1 mm Figure 3-3. The
central hemocytometer counting area contains 25 large squares and each one has 16 smaller
squares. Cells were counted only on the lines of two sides of the large square in order to avoid
counting cells twice. Dead and viable cells were distinguished according to their shape and size.
Cell concentration was calculated using the following formula:

Total cells/ml = (Total cells number / No. of Squares) × 10000 cells/ml

Figure 3-3. Hemocytometer counting cell
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Dark Cytotoxicity

In 96-well black wall clear bottom plates (Corning, USA) HCT-116 cells were seeded at
8 × 104 cells/well and incubated for 48 hours. For dark cytotoxicity experiment, PAG-PEG was
diluted to 1.5 M, 3.12 M, 6.25 M, 12.5 M 25 M, 50 M, and 100 M from the stock
solution; SiN-NH-PAG was diluted with different concentrations starting with 0.6 M, 1.25 M,
2.5 M, 5 M, 10 M, and ending with 20 M. Cells were then incubated with diluted PAGPEG or SiN-NH-PAG for another 24 hours as shown in Figure 3-4. Cell viability was
determined by adding 20 L of CellTiter 96 Aqueous One Solution Reagent (Promega, USA)
into each well, followed by further incubation for 2 h. Absorption at 490 nm was measured for
the corresponding MTS-fomazan with a SpectraMax M5 Microplate Reader. The results were
then compared with a control, which was incubated in the absence of the PAGs to calculate
relative cell viability.

Figure 3-4. Dark cytotoxicity cell culture scheme, using 96-well black wall clear bottom plates.
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Photo Cytotoxicity
For photocytotoxicity experiment, 50 M of PAG-PEG or 10 M SiN-NH-PAG was
added to the HCT-116 Cells as shown in Figure 3-5. The 96-well black well plate was placed on
an inverted microscope (Olympus IX81) coupled with a 100 W mercury lamp. The distance
between the bottom of the plate and the objective was set at 1 cm in order to irradiate the whole
well with UV light. A customized filter cube was employed (Ex 377/50, DM 409, Em 460/50) to
excite PAG. The final power reaching the plate was 5.4 mW/cm2. Different irradiation times
were used (0 min., 1 min., 5 min., and 10 min.). After irradiation, the plate was incubated for
another 24 hours before the cell viability was measured.

Figure 3-5. Photocytotoxicty cell culture scheme using 96-well black wall clear bottom plates.

52

Lysosome Colocalization
In 12 mm poly-D-lysine functionalized coverslips HCT-116 cells were cultured for 48 hours.
PAG-PEG was then added into the cells at a concentration of 50 μM with LysoTracker Green at
2 μM for 1 hour. After that, coverslips were washed with PBS two times. Coverslips were
imaged using Olympus IX-81 confocal microscope. A customized filter (377/50, 409, 460/50)
was used for PAG-PEG and (Ex 477/50, DM 507, DM 536/40) was used for LysoTracker green.

Live Cell Imaging of PAG-PEG and SiN-NH-PAG
In 40 mm poly-D-lysine functionalized coverslips, cells were cultured for 48 hours. After
that, PAG-PEG or SiN-NH-PAG was added to the cells. 24 hours later, the coverslip was washed
with PBS twice and set onto a bioptics live cell-imaging chamber. After irradiation with UV
lamp for 2000 ms (5.4 mW/cm2) cells were imaged with confocal microscope (Olympus IX-81)
at 1 min interval for 4 hours by using DIC channel. Cells were kept in 37 0C RPMI-1640 whole
culture medium with 5% CO2, while imaging.

Calculation of the Increasing in Acidic Contain of Lysosome
In order to calculate the increasing in the acidic contain of lysosome in vivo, cells were
incubated with PAG-PEG at 50M concentration for 24 hours. Then, 2mM of LysoSensor Green
(Invitrogen, USA) was added for another 2 hours. After 2000 ms irradiation, cells were imaged
at 1 min interval for 60 min with FITC filter cube (Ex 477/50, DM 507, DM 536/40) to collect
fluorescence of LysoSensor Green. The fluorescence intensities were calculated at different time
points with SlideBook. Cells were kept in 37 0C RPMI-1640 whole culture medium with 5%
CO2, while imaging.
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Estimation of Lysosomal pH Drop
The pH drop in Lysosome was measured according to method reported by Zhu et al.74
A solution of PAG-PEG (50μM) and Rh B Base (0.1mM) in DCM was mixed in the dark and
exposed in order to make a dose dependent calibration curve. By assuming the number of acid
molecules generated the same as the number of Rh B Base molecules converted to Rh B+.

3.3

Results and Discussion

Dark Cytotoxicity of SiN-NH-PAG and PAG-PEG
An ideal phototherapeutic agent needs a PAG compound that exhibits low cytotoxicity in
the absence of light and induces high percentage of cell death when illuminated at certain
wavelength. In order to evaluate the intrinsic toxicity of the PAGs, an assay of cell viability was
done in the dark (dark viability) to prevent the production of photoacid and enabling the choice
of suitable concentration for photodynamic therapy.
The cytotoxicity was evaluated using a standard MTS assay.86 HCT-116 (human
colorectal carcinoma) were incubated with different concentrations of 1.5, 3.12, 6.25, 12.5, 25,
50, 100μM solutions of PAG-PEG in medium for 24 h at 37 0C. As shown in Figure 3-6, cell
viability of HCT-116 Cells incubated with up to 100 μM of PAG-PEG were quite close to
100%, which means that PAG-PEG at that concentration exhibited almost no level of
cytotoxicity.
Different concentrations of SiN-NH-PAG 0.62, 1.25, 2.5, 5, 10, and 20 μM were also
incubated with HCT-116 cells in medium for 24 h at 37 0C and the results indicates that
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SiN-NH-PAG with up to 10 μM was close to 100% viability as shown in Figure 3-7 which
indicated that SiN-NH-PAG at that concentration also exhibited almost no level of cytotoxicity.
Even higher concentrations of SiN-NH-PAG were not able to do much damage to cells. After
incubation with 20 μM about 77% of HCT-116 cells were still viable.
All these data above demonstrate that the dark cytotoxicity of both PAG-PEG and
SiN-NH-PAG are very low making them suitable for being applied to photodynamic therapy
experiments.

Dark Viability (%)

Dark Cytotoxicity of PAG-PEG with HCT-116
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Figure 3-6. Dark cytotoxicity of HCT-116 cells incubated with PAG-PEG and exhibit low
cytotoxicity
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Figure 3-7. Dark cytotoxicity of HCT-116 cells incubated with SiN-NH-PAG and indicates low
cytotoxicity at 10 μM.

Photo Cytotoxicity of SiN-NH-PAG and PAG-PEG
Photo-cytotoxicity was achieved (exposure experiment) by using 50μM concentration of
the PAG-PEG. This concentration exhibited the most appreciable changes in viability (from
dark viability to postexposure viability) Figure 3-6.
As shown in Figure 3-8, HCT-116 cells incubated with 50 μM of PAG-PEG with 10
min exposure, promoted a drop from 97% viability to 64% viability, a result consisted with the
photoacid quantum yield (Table 2); the cell death induction was directly proportional to the
amount of acid generated. For SiN-NH-PAG, 10μM concentration was used since this
concentration showed the most appreciable changes in dark viability Figure 3-7; cells were
incubated with 10μM concentration of SiN-NH-PAG. As shown in Figure 3-9, within 10 min
exposure promoting a drop from 98% viability to about 42% viability.
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Based on the results from the photocytotoxicity experiments, we indicate that
SiN-NH-PAG works more efficiently as a PDT agent than PAG-PEG; even though the
concentration of SiN-NH-PAG was 10 μM, which was less than the concentration of PAG-PEG
(50 μM). Solubility of nanoparticles was found to be higher in comparison to the single
molecular PAG due to the salt form of this sulfonium PAG results in increased solubility of silica
nanoparticles.

A comparison of the silica nanoparticles SiN-NH-PAG and single molecules

PAG-PEG shows that the former have a greater efficacy at a concentratio

. Our

construction of these nanoparticles is based on the surface modification of the silica surface with
amine groups followed by the addition of the PAG molecules via amid links. The increased
effectiveness of the nanoparticles is assumed to be because the large number of PAG groups
present on the nanoparticles resulting in a greater number of PAGs present per unit volume of
substrate compared to the single molecule species. Also the biocompatibility and high efficiency
taken up of silica nanoparticles by cells add more efficient properties for PAG agent.

Figure 3-8. Postexposure viability of HCT-116 cells with 50 μM of PAG-PEG concentration
exhibited low intrinsic (dark) cytotoxicity and high postexposure cytotoxicity.
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Figure 3-9. Postexposure viability of HCT-116 cells with 10 μM of SiN-NH-PAG
concentration exhibited low intrinsic (dark) cytotoxicity and high postexposure
cytotoxicity

Colocalization of PAG and LysoTracker Green
In order to investigate and know where the PAG-PEG travels to inside HCT-116 cells,
cells were incubated with PAG-PEG and LysoTracker Green. PAG-PEG fluorescence was
collected inside cells (Figure 3-10, C), showing a good uptake efficiency of PAG-PEG. Overlay
image (Figure 3-10, D) exhibited a good colocalization between PAG-PEG and LysoTracker
Green, and indicated PAG-PEG mainly built in lysosomes.
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A

C

B

D

Figure 3-10. DIC (a) and confocal fluorescence micrographs of HCT-116 cells incubated with
PAG-PEG using (50 M) and (b) Lysotracker Green. (c) Shows the PAG-PEG in cells and
colocalization in d (overlay of b and c) with Lysotracker green shows the PAG-PEG mainly
build up in lysosomes and endosomes. Using scale bar 50 m.
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The Increasing in Acidic Contain of Lysosome
LysosSensor Green has been reported to be an acidic pH monitoring dye within the
cells.25 We used this dye to verify the decreasing in the lysosomal pH. The quantum yield of
LysoSensor Green is known to increase when the acidic compartment increased.25 The increase
in the fluorescence intensity as a function of exposure was indeed observed within the cells that
were incubated with PAG-PEG (50 μM) and LysoSensor Green. This indicates a drop in internal
lysosomal pH (of already acidic compartments) followed by irradiation in HCT-116 cells. The
drop in the fluorescence intensities as a function of irradiation dose in control HCT-116 cells can
be attributed to the photobleaching of the pH indicator, which is acidified by the acidic character
of the lysosomes (Figure 3-11).
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Figure 3-11. Acidic content increasing in the lysosomes as a function of exposure dose in HCT116 cells incubated with PAG-PEG (50 M) for 24 h and with 2 M of LysoSensor Green 2 h.
after 5 s irradiation, 5.4 mW/cm2. (C,D,E,F) cells were imaged with 1 min intervals time for 60
min with FITC channel. SlideBook was used to calculate the intensities at different time points.

61

Estimating Lysosomal pH Drop
It is assumed that the number of acid molecules generated by PAG is the same as the
number of Rhodamine B base molecules converted to Rhodmiane B+, this causing an increase in
absorption peak around 555 nm. We estimate that 50 μM concentration of PAG-PEG would at
least generate 9.1 × 10

-6

M of H+ using radiation dose (10 min). This radiation dose caused cell

viability to be reduced to 64%. The lysosomal pH would conservatively be reduced by at least
0.3 pH units to be approximately pH ≤ 4.4 inside the lysosomes and this is undoubtedly a good
event as most cells underwent necrosis. The generation of acid molecule was measured to be 9.1
x 10-6 M by extrapolation of the calibration curve as shown in Figure 3-12.

Figure 3-12. A solution of PAG-PEG (50 μM) mixed with Rh B Base (0.5 mM) was exposed to
prepare a dose dependent calibration curve using 5.4 mW/cm2 power light.

62

Excitation of PAG in Cell Free System with LysoSensor Green
In order to demonstrate that the PAG-PEG causes an increase in the acidic content of
lysosomes, and eventually increases the fluorescence intensity of LysoSensor Green in cell free
system, we mixed around 150 μM of PAG-PEG with LysoSensor Green and then measured the
fluorescence intensity at 0 min of irradiation using EDINBURGH INSTRUMENTS FLS980
spectrofluormiter and later on irradiated the mixture at 1 min, 2 min, and 3 min using LOCTITE
at 5.4mW/cm2 power light. We recognized that the fluorescence intensity of LysoSonser green
increased as time of radiation increased as shown in Figure 3-13.

Figure 3-13. Mixing of 150 μM PAG with Lysosensor green in cell free system using different
time of irradiation its indicates that the fluorescence intensity of LysoSensor green dye increased
as a time of irradiation increased.
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Cell Death and Live Cell Imaging
Cell death by PAG-PEG was demonstrated by live cell imaging experiment in which,
HCT-116 cells were incubated with 50 μM concentration of PAG-PEG for 24 h at 37 0C. Timelapse images were taken in order to show the process of cell death by PAGs after light
irradiation.
Cells were irradiated with (2000 ms) (5.4mW/cm2) and imaged with confocal
microscope (Olympus IX-81) at 1 min intervals for 4 hours by using DIC channel. Figure 3-14
shows the progressive change in the cells morphology after the generation of photoacid. Loss of
the cell adhesion (yellow arrows) is followed by a blebbing – like activity (blue arrows). The
integrity of the nuclei in these cells is a sign that chromatin condensation is not occurring;
therefore, the process is not apoptotic. After that, the cell was swelling significantly which is
characteristic of necrosis (red arrows). This experiment was repeated and applied again with
10μM concentration of SiN-NH-PAG incubated with HCT-116 cells for 24 h and showed the
same behavior with PAG-PEG (Figure 3-15).
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Control
Figure 3-14. HCT-116 Human Colorectal Carcinoma cells incubated for 24 h with PAG-PEG
(50 μM). Confocal microscope (Olympus IX-81) at 1 min intervals for 4 hours by using DIC
channel. Yellow arrows show loss of cell adhesion, bule arrows show blebbing – like activity,
and red arrows cell swelling. Scale bar is 50 μm .
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Control
Figure 3-15. HCT-116 Human Colorectal Carcinoma cells incubated for 24 h with
SiN-NH-PAG (10 μM). Confocal microscope (Olympus IX-81) at 1 min intervals for 4 hours by
using DIC channel. Yellow arrows show loss of cell adhesion, blue arrows show blebbing – like
activity, and red arrows cell swelling. Scale bar μm 50.
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3.4

Conclusions

The use of photoacid generators to induce cell death by making a grave pH imbalance in
cells has been reported. We demonstrated that sulfonium-based PAGs can be used to selectively
induce cell death during photoexcitation and this will open the possibility of inducing cell death
in an oxygen-independent manner. More exclusively, PAG-PEG and SiN-NH-PAG have induced
necrotic cell death via generation of photoacid in the lysosomes in HCT-116 cells. SiN-NH-PAG
has showed a greater efficacy at a concentration of 10 M compared with single molecule
species PAG-PEG 50 M. This assumed to be because the large number of PAG groups present
on the nanoparticles. Resulting in a greater number of PAGs present per unit volume of substrate
compared to the single molecule species.
H+ molecules were generated using 1PA since the simplicity of that associated with
generating photoacid. Also one photon photoacid generation is more effective process; the
excitation source that needed for this process is cheaper and easier to use. 1PA is also an
advantage because a large amount of targeted surface mass can be converted within tissue at a
faster rate.
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CHAPTER 4. SELECTIVE NANO-SENSING APPROACH FOR THE
DETERMINATION OF INORGANIC PHOSPHATE IN HUMAN URINE SAMPLES

4.1

Introduction

The level of phosphate metabolites in cells can be used as an indicator of dysfunctions
and/or disorders in biological systems.87 Abnormal levels of phosphate in urine samples are also
related to the development of certain types of cancer affecting several organs of the human body,
including breast, pancreas, lung and thyroid. As such, the development of assays that can
determine phosphate on real-time bases is essential to biochemical studies as well as clinical
diagnosis.
Scheme 4-1 illustrates the concept of the proposed sensor, which is based on Fluorescence
Resonance Energy Transfer (FRET). The Terbium-Ethylenediaminetetraacetic acid complex
[Tb-EDTA]-1 is used as a luminescence donor probe. Gold nanoparticles (Au NPs) capped with
Cetyltrimethylammonium bromide (CTAB) are used as acceptors with positive charges on the
surface. Hydrophilic and electrostatic interactions between [Tb-EDTA]-1 ions and Au NPsCTAB provide the close proximity between donor and acceptor that is needed for FRET to occur
and quench the luminescence of Tb[EDTA]-1 (sensor off). The interaction between phosphate
ions and CTAB displaces Tb[EDTA]-1 from the proximities of Au NPs to the extent that FRET
does not longer occurs (sensor on).
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FRET

phosphate ions

Au

Au

[Tb-EDTA] -1, Sensor ((ON))

[Tb-EDTA] -1, Sensor ((OFF))
Au nanoparticles Capped with CTAB

phosphate ions

Scheme 4-1. Sensing approach based on Fluorescence Resonance Energy Transfer (FRET)
between [Tb-EDTA]-1 and Au NPs followed by chemical displacement of [Tb-EDTA]-1 by
phosphate ions at the head of CTAB receptors.

FRET involves a mechanism in which the energy of the emitting donor will transfer via
non-radiative dipole-dipole interaction to an acceptor. The efficiency of FRET is inversely
proportional to the sixth power of the distance (R-6) between donor (fluorophore) and the
acceptor (quencher) within 10-100 Å. During the process of energy transfer, the proximity
between donor and acceptor reduces the quantum yield of the donor’s emission. When the
distance increases, the intensity of emission is effectively restored.88 This technique is often used
in biochemistry and structural biology to study macromolecular complexes of DNA, RNA, and
proteins.89-90 Au NPs have demonstrated excellent potential as bio-sensing platforms for a wide
range of applications varying from chemical to biological samples.91-95 This popularity is
partially due to the possibility of functionalizing the surface of Au NPs with peptides, proteins
and antibodies that provide the required specificity toward cellular targets in complex biological
matrixes. The achievement of additional selectivity is possible by using fluorescent dyes
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optically active in the near-infrared, a wavelength region with relatively lower spectral
interference from biological matrixes.

96,97

Our approach is based on time-resolution techniques. The long-lived luminescence of
lanthanide ions (particularly Tb3+ and Eu3+), which occurs in the milliseconds time domain,
makes possible to time-discriminate against short-lived background fluorescence and scattered
excitation light with rather simple, off-the-shelve, commercial instrumentation. Since their
emission results from shielded electronic transitions (f-orbital manifold), the luminescence
intensity of Eu3+ and Tb3+ has shown less susceptibility to oxygen quenching than traditional
fluorescent dyes.

98-101

CTAB is an amine based cationic quaternary surfactant often used to avoid aggregation
of Au NPs in aqueous solution via electrostatic repulsion. CTAB molecules show strong
chemical affinity for phosphate ions that makes them selective receptors in the presence of other
inorganic ions.102
Although individual elements of our approach have been anticipated and implemented
previously, the optimal combination of these features has not been realized and the techniques
have generally not been practical enough for straightforward implementation. The main
significant aspect of our proposition is the practical, smooth way we are integrating all these
features together.
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4.2

Materials and Methods

All the reagents and solvents were purchased from different commercial providers and
used without further purification. Sodium phosphate (Na3PO4), sodium acetate, sodium fluoride,
and sodium sulfite were obtained from Aldrich. Sodium carbonate, urea, creatinine, sodium
nitrate, sodium hydroxide, and sodium iodide were obtained form Alfa-Aesar. Nanopure water
was also used throughout obtained from a Barnstead Nanopure Infinity water purifier.
Instrumentation
Excitation and emission spectra were recorded with a commercial spectrofluorimeter
(FluoroMax-P from Horiba Jobin-Yvon) equipped with a continuous 100 W pulsed xenon lamp
with broadband illumination from 200 to 1100 nm. The excitation and emission monochromators
had the same reciprocal linear dispersion (4.2 nm·mm-1) and accuracy (±0.5 nm with 0.3 nm
resolution). Both diffraction gratings had the same number of grooves per unit length (1200
grooves·mm-1) and were blazed at 330 nm (excitation) and 500 nm (emission). A photomultiplier
tube (Hamamatsu, model R928) with spectral response from 185 to 650 nm was used for
fluorescence detection operating at room temperature in the photon- counting mode. Commercial
software (DataMax) was used to computer-control the instrument. Measurements were made by
pouring un-degassed liquid solutions into micro-quartz cuvettes (1 cm path length x 2 mm width)
that held a maximum volume of 400 L. Fluorescence was collected at 90° from excitation using
appropriate cutoff filters to reject straight-light and second order emission.
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Synthesis of Gold Nanoparticles (Au NPs) capped with CTAB
The synthesis of the Au NPs was carried out via a method similar to the one reported by
Nikoobakht. 103 The modifications implemented in these studies are shown in scheme 4-2. All
glassware was washed with aqua-regia (1:3 HNO3/HCl v/v) to remove the presence of any gold
crystals. A seed solution was prepared with 1mL of 2.0M CTAB and 1mL of nanopure water.
In order to keep the CTAB from precipitating out, the solution was heated to about 35 oC. 18uL
of 0.029M HAuCl4 was added to the CTAB aqueous solution, which became yellow in color and
was mixed slowly. 120uL of ice-cold 0.010 M NaBH4 was then added to the mixture causing the
color to turn brown. Prior to use, the seed solution was allowed to mix for ½ hour.
Growth solutions were prepared in 10mL beakers by adding 5mL of nanopure water and
5mL of 2.0 M CTAB. The growth solutions were mixed and heated to about 35oC to avoid
CTAB precipitation. 180 uL of 0.029M HAuCl4 were added and stirred until the solution
appeared homogenous. 60, 70, or 80uL of 0.0788M Ascorbic Acid were then added to different
growth solutions to test which concentration of Ascorbic Acid would be optimal. 20, 30 or 40uL
of seed solution were transferred to the different growth solutions to find out the optimal volume
of seed solution. The resulting mixtures were agitated for several seconds to disperse the seed
evenly and then allowed to sit for about 10 minutes during which the color changed from clear to
deep purple. After 10 minutes the solutions were removed from the heat source and kept at room
temperature until further use.
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Scheme 4-2. Synthesis of Gold nanoparticles in CTAB micelles.

Characterization of Gold Nanoparticles (Au NPs)
4.2.3.1 UV-vis Characterization
The synthesized Au NPs were characterized via absorbance spectroscopy using a Cary 50
spectrophotometer equipped with a 75-W pulsed Xenon lamp (spectral radiance of 190-1100nm),
a monochromator (fixed optical band-pass of 1.5nm), a beam-splitter and two silicon photodiode detectors.

4.2.3.2 Particle Size
The particle size distribution of Au NPs was obtained via light scattering with a Zetasizer
Nano ZS9 instrument purchased from Malvern .
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Preparation of [Tb-EDTA]-1 (probe)
Stock solutions of Tb3+ and EDTA-4 in HEPES buffer pH 7.4 were prepared at a
concentration of 10-3 M. In order to obtain the maximum luminescence signal from the
[Tb-EDTA]-1 complex, various mixtures with the following concentration ratios of 10-3 M Tb3+
and 10-3 M EDTA4- were prepared: 1:0, 1:0.25, 1:0.5, 1:1, 1:1.5. The resulting mixtures were
shaken for 5 minutes prior luminescence measurements. After selecting the best Tb3+-EDTA4ratio, serial dilutions were made to reach final Tb3+ concentrations equal to 10-4, 10-5 and 10-6 M.
Sensor Preparation
350L of Au NPs-CTAB stock solution (optical density = 0.74 OD) were added to
150L of a 10-5 M [Tb-EDTA]-1 solution. After 5 minutes of mechanical shaking, the mixture
was ready to use for phosphate sensing.

Interference studies
The following chemical species were tested for possible interference at the 75x 10-5 M
concentration: PO4-3, NO3- , NO2- , CH3COO- , OH- , CO32- , Cl- , SO3-2, F-, I-, Urea, and
Creatinine.
Urine Analysis
Urine samples from healthy, non-smoking volunteers were used as representative clinical
samples. Urine samples were prepared following a previously reported procedure

95

and used

within one hour of sample collection. After two filtration cycles with filter paper Whatman #50,
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the concentration of phosphate ions in each sample was determined via the multiple standards
addition method.
4.3

Results and Discussion
Sensing Mechanism

As shown in Figure 4.1, the absorption spectrum of Au NPs-CTAB displays a strong
Surface Plasmon Resonance (SPR) absorption band with maximum wavelength at approximately
541 nm. The overlapping of this absorption band with the luminescence spectrum of
[Tb-EDTA]-1 is an essential condition to promote FRET between the donor and the acceptor.
Hydrophilic and electrostatic interactions between [Tb-EDTA]-1 and Au N-CTAB provide the
close proximity that is needed for FRET to occur and quench the luminescence of Tb[EDTA] -1
(sensor off).

Figure 4-1. (A) UV-vis absorption spectrum of Au NPs-CTAB; and (B) luminescence emission
spectrum of Tb-EDTA.
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The interaction between phosphate ions and the CTAB displaces Tb[EDTA] -1 from the
proximities of Au NPs to the extent that FRET does not longer occurs. As a result, the
luminescence signal of the donor increases (sensor on) as shown in Figure 4.2.

Figure 4-2. Luminescence signal (blue) and after (red) the addition of 75 × 10-5M of inorganic
phosphate to the optimized sensor using Ex/Em 240/545 nm, band pass 15/5 nm, Tg 9.00 ms and
Td 0.01 ms
Synthesis of gold nanoparticles in CTAB micelles
The synthesis of Au NPs was monitored via UV-vis absorption spectroscopy. The optical
density of the SPR band at 541nm reached maximum intensity with 70uL of Ascorbic Acid and
30uL of seed solution. Upon addition of 70uL or more of ascorbic acid, the solution changed
colors from yellow to colorless indicating that the growth solution had been completely reduced.
Volumes of Ascorbic Acid lower than 70uL caused the solution to remain yellow indicating that
it was not fully reduced. Volumes of seed solution lower than 30uL yielded nanoparticles with
the desired dimensions – i.e. SPR maximum wavelength ~ 541nm - but a lower concentration
than the optimum concentration at maximum optical density. Volumes of seed solution higher
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than 30uL created smaller spheres that did not absorb at the desired wavelength range. The
excess of CTAB and reactants was removed from the final solution via centrifugation. It was
observed that three centrifugation cycles at 13,000 rpms for 30 minutes allowed the sensor to
function while still keeping the nanoparticles from aggregating.

Particles size of Gold nanoparticles
Figure 4-3 shows the particle size distribution obtained from three light scattering
measurements of three Au NPs-CTAB solutions produced by the synthetic protocol described
previously. The size distribution of Au NPs ranges from 10 - 70 nm with an average mean size of
approximately 25 nm. This average size is consistent with the maximum wavelength of the SPR
absorption band at 541nm104.

AuNPs-CTAB

Figure 4-3. Number-averaged particle size distribution of Au NPs-CTAB.
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Optimization Studies
4.3.4.1 Optimization of Signal to Background Ratio for Analytical Use
The coordination of water molecules to Tb3+ quenches the luminescence signal of the
lanthanide ion. The maximum luminescence signal is obtained when the ligand EDTA4- removes
all the water molecules from the coordination sphere of Tb3+ 105. As shown in Figure 4-4A, the
maximum luminescence signal is obtained for a Tb3+-EDTA4- molar ratio of 1:1. At this molar
ratio and upon excitation at 235nm, [Tb-EDTA]-1 provides a spectral signature with an
acceptable signal-to-background (S/B) ratio for analytical use. Optimization of instrumental
parameter for best S/B ratio resulted in 20 excitation pulses per data point, a 15/5nm excitation/
emission band-pass, and delay (Td) and gate (Tg) times of 0.01 and 9ms, respectively.

A
B

Figure 4-4. (A)Signal intensity of Tb3+ at various EDTA4- concentration ratios. Measurements
were made with a 10-5M Tb3+ solution in HEPES buffer at pH 7.5. (B) Time-resolved spectra of
10-3M of Tb-EDTA in HEPES buffer. Ex/Em 234/545 nm, band pass 15/5 nm, delay (Td)
0.01 ms and gate (Tg) times 9 ms, respectively.
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4.3.4.2 Optimization of probe displacement time
Figure 4-5 shows the signal intensity of Au NPs – CTAB – [Tb-EDTA]-1as a function of
shaking time after adding phosphate ions to the sensing solution. All solutions were shaken at
1,200rpm. For a 10-5M Tb-EDTA-1 solution and within the concentration range of phosphate ions
tested (25-75×10-5 M), the time it took to reach the maximum signal depended on the
concentration of phosphate ions. The shortest time (3 min) was obtained with the highest
phosphate ion concentration (75×10-5M). In order to provide enough time for the complete
displacement of [Tb-EDTA]-1, all further measurements were carried out after 10 min of shaking
time.

Figure 4-5. Signal intensity of Au NPs-CTAB-[10-5M [Tb-EDTA]-1 as a function of shaking
time.
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Interference Studies

Potential matrix interference was investigated by comparing the response of the senor in
the absence and the presence of several chemical species commonly found in urine samples.
Their concentrations were adjusted to mimic the natural composition of human urine. The
obtained results are shown in Figure 4-6. With the exception of the phosphate ion, all the other
species provided signals with statistically equivalent intensities to the one of the control signal
(P = 95%; N1 = N2 = 3). The obtained results indicate that the investigated ions do not release
[Tb-EDTA]-1 from the positive charges of the CTAB receptors into the bulk of the sensing
solution. This is probably due to a lower chemical affinity between the potential interference and
the CTAB receptor. When compared to the Tb-EDTA-1 complex and the studied interference, the
higher affinity of the phosphate ion for the CTAB receptors could be attributed to tetrahedral
shape of the predominant phosphate species in solution (HPO42-), which makes its negative
charge more polarizable than the other investigated anions. 102,106,107

Figure 4-6. Comparison of luminescence intensities in the absence and the presence of potential
interference at the concentrations commonly found in urine samples, namely 10-4M for all the
ions with the exception of urea (10-3M). All measurements were made with a 75x01-5M sensing
solution

80

Analytical Figures of Merit
.
A calibration curve was built in HEPES buffer pH 7.5 with external standards containing
different concentrations of phosphate ions (PO4-3) and fixed concentrations of creatinine, urea,
NO3-, Cl-, F-, SO3-2, CO3-2, OH- and I-. The concentrations of concomitants mimicked those in
real urine samples, namely10-4M for all the ions with the exception of urea (10-3M). The direct
correlation that was observed between signal intensity and the phosphate concentration is shown
in Figure 4-7. Linear regression via the least squares method provided a linear dynamic range
(R2 = 0.9894) ranging from 6.3x10-6M to 7.5×10-4M. The limit of detection (1.8 uM) was
calculated as 3SB/m; where SB is the standard deviation of 16 blank measurements and m is the
slope of the calibration curve.

Figure 4-7. Luminescence spectra (left) and signal intensities (right) at different phosphate
concentrations.
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Urine Analysis
Urine analysis was carried out via the multiple standard additions method. Urine samples
were diluted 70 times to reach a final volume of 500uL. All measurements were made in HEPES
buffer pH ≈ 7.5. Multiple standard additions were carried out with µL volumes of a 0.025M
(PO4-3) standard solution. Figure 4-8 shows the multiple standard additions plot. The best linear
fit was obtained with the least squares method. Comparison of the linear equations obtained from
the calibration curve and the multiple standard additions plot shows the same slope (3x107). This
is a strong indication of the lack of chemical interference in the urine sample. The concentration
of phosphate found in the urine sample (399  24 mgL-1) was within the reported values of urine
samples collected from healthy individuals.

Figure 4-8. Standard addition calibration plot for the determination inorganic phosphate in
human urine.
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4.4

Conclusion

A novel sensor for inorganic phosphate in urine samples was developed that takes
advantage of the FRET that occurs between [Tb-EDTA]-1 (donor) and Au NPs capped with
CTAB acceptors. The limit of detection (1.8uM) was within the concentration range of sensing
approaches reported previously. The main advantages of the proposed sensor relate to its
selectivity, simplicity of operation and analysis time. The new sensor presented no interference
from chemical species commonly found in urine samples, including creatinine, urea, NO3-, NO2-,
OH-, CO3-2, SO3-2, Cl-, F-, CH3COO-, and I-. The simplicity of analysis provides an approach
well-suited for “real-time” monitoring of phosphate ions. Analysis time is made possible within
approximately 10 min per sample.
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CHAPTER 5. FUTURE WORK
Future applications for chapter two and three can be focused on encapsulating silica
nanoparticles with 2PA imaging probes and PAG and functionalized the surface of silica
nanoparticles with site specific tumor cell like RGD peptide or folic acid and applying this agent
on live animal experiment. Furthermore, using of a windows chamber results better comparison
by tracking the cancer progression on the individual model. The PDT agent can be irradiated
through windows chamber and treatment efficiency can be estimated by measuring the tumor
sizes.

Figure 5-1. Introducing of the window chamber on the skin of the mouse.108
Future work can also be focus on the conjugation of synthesized PAG-NH-Boc
Figure 5-1 with proper polymer. This polymer can also be conjugated with RGD peptide and
2PA imaging probes. RGD peptides have been well known for their selective binding properties
with vasculatures of tumor cells. 2PA imaging probes can be used due to the deep penetration of
2PA excitation. This way, the therapeutic agent (PAG) can be tracked by the imaging probes.
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RGD and PAG-NH-Boc can be introduced to the polymer by applying Nhydroxyscuccinimide on one of the monomers termini to react with the primary amine group
PAG and RGD (a lysine residue). As a result, polymer with 2PA fluorescence probes and PAG
agents with RGD peptide are proposed for live animal experiment work.

Figure 5-2. Structure of PAG-NH-Boc.
PAG 9 can also be conjugated with RGD peptide by introducing N-hydroxyscuccinimide
on the PAG 9 and coupled with RGD as shown in scheme 4-1

RGD =
RGD =
Scheme 5-1. PAG 9 conjugated with RGD peptide.
RGD =
RGD =
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Future work on the phosphate sensor (chapter 4) will be focused on developing an
antenna capable to enhance the luminescence emission of the [Tb-EDTA]-1 probe. The
enhancement of the luminescence signal will allow the detection of lower [Tb-EDTA]-1
concentrations in the bulk of the sensing solution. A lower range of detectable concentrations of
released [Tb-EDTA]-1 is expected to correlate to lower concentrations of phosphate ions and,
therefore, better limits of detection.
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APPENDIX CHAPTER TWO
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